Vanguard Personalized Indexing Management LLC Purchases 4,506 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Vanguard Personalized Indexing Management LLC grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 41.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,361 shares of the medical equipment provider’s stock after purchasing an additional 4,506 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Zimmer Biomet were worth $1,869,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of ZBH. Schechter Investment Advisors LLC increased its stake in Zimmer Biomet by 21.6% in the third quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider’s stock valued at $476,000 after purchasing an additional 752 shares in the last quarter. Atria Wealth Solutions Inc. lifted its holdings in Zimmer Biomet by 5.9% during the third quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider’s stock worth $2,312,000 after acquiring an additional 1,144 shares in the last quarter. International Assets Investment Management LLC grew its stake in Zimmer Biomet by 11,244.9% in the fourth quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock valued at $8,146,000 after acquiring an additional 66,345 shares during the period. Amalgamated Bank raised its position in shares of Zimmer Biomet by 3.0% during the third quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock worth $6,303,000 after purchasing an additional 1,631 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of Zimmer Biomet by 37.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock valued at $18,981,000 after purchasing an additional 42,539 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $121.23 on Friday. The stock has a market capitalization of $24.94 billion, a PE ratio of 26.24, a PEG ratio of 2.18 and a beta of 1.03. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $147.50. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80. The business’s 50 day simple moving average is $124.46 and its 200 day simple moving average is $121.03.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the prior year, the firm posted $1.89 earnings per share. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet’s payout ratio is 20.78%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ZBH shares. Barclays increased their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research report on Monday, February 12th. Truist Financial lowered their price objective on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a report on Friday, May 3rd. Royal Bank of Canada restated an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 9th. Citigroup lifted their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Finally, StockNews.com cut Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $135.40.

Insider Transactions at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.95% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.